Clinical Trials Browser

NIH × Carcinoma, Neuroendocrine × Sunitinib × Clear all

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors